To hear about similar clinical trials, please enter your email below
Trial Title:
Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients
NCT ID:
NCT05680194
Condition:
Breast Cancer Female
Conditions: Official terms:
Breast Neoplasms
Diphosphonates
Conditions: Keywords:
≥65 Years Old
early breast cancer
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Procedure
Intervention name:
operation
Description:
operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection,
sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC,
capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM,
Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
Other name:
chemotherapy
Other name:
radiotherapy
Other name:
endocrine therapy
Other name:
targeted therapy
Intervention type:
Drug
Intervention name:
Bisphosphonate
Description:
Bisphosphonate
Summary:
The elderly patients over 65 years old with breast cancer have concomitant diseases, poor
tolerance to conventional treatment, and the specific prognosis of breast cancer is
relatively good. Previous studies on breast cancer have almost excluded elderly breast
cancer patients, and conventional treatment schemes cannot meet the clinical diagnosis
and treatment needs of elderly breast cancer patients. The establishment of a prognosis
model for elderly breast cancer patients can provide personalized treatment programs.
This is important for prolonging the survival time of patients and improving the quality
of life. This project plans to observe the relationship between prognosis and
pathological staging, molecular typing, and concomitant diseases of elderly breast cancer
patients in combination with immune genes, and establish a prognosis model of elderly
breast cancer and verify it. This project is expected to establish a new prognostic model
for elderly breast cancer patients, accurately judge the prognosis of patients, and
provide a new basis for hierarchical and personalized treatment of elderly breast cancer.
Criteria for eligibility:
Study pop:
the patients ≥65 Years Old with breast cancer who received operaion in Peking Union
Medical College Hospital
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- female patients with breast cancer
- ≥65 Years Old
- patients with breast cancer received operation in Peking Union Medical College
Hospital
- treatment regimen was made in Peking Union Medical College Hospital
Exclusion Criteria:
- patients with metastasis
- patietns with recurrence
- patients without pathological information
Gender:
Female
Minimum age:
65 Years
Maximum age:
100 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Peking Union Medical College Hospital
Address:
City:
Beijing
Country:
China
Status:
Recruiting
Contact:
Last name:
Ying Zhong
Phone:
0086-01069158720
Email:
bakenfish@163.com
Start date:
April 1, 2022
Completion date:
December 1, 2025
Lead sponsor:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Source:
Peking Union Medical College Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05680194
